Wed, Jun. 1, 1:18 PM
- Myriad Genetics (MYGN +1.4%) acquires Koln, Germany-based Sividon Diagnostics for €35M in upfront cash and potentially up to an additional €15M in performance-based milestones.
- Sividon, spun out of Siemens Healthcare Diagnostics in 2010, markets an RNA expression test called EndoPredict that evaluates 12 genes to assess the aggressiveness of breast cancer on a molecular level. It is currently CE Mark'd on the Siemens Versant instrument, but Myriad intends to transition it to Thermo Fisher's (TMO +0.5%) QuantStudio platform.
May 6, 2011, 9:48 AM
Morningstar sees plenty of debt capital capacity available at attractive terms to fund leveraged buyouts, which should lead to resurgence in M&A activity among private equity groups. Its latest list of top takeover candidate investment ideas: ATLN, AKAM, AEO, CLWR, CLD, LEAP, MYGN, HK, RRC, SNV.| May 6, 2011, 9:48 AM